Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events
Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal
Pfizer's new vaccine candidate showed strong protection against 25 types of pneumococcal bacteria in infants. This is progress, and investors should watch whether regulators approve it for real world use.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.